Biocompatibility: Is it a Relevant Consideration for Today's Haemodialysis?

Abstract

Get full access to this article

View all access options for this article.

References

Kaplow

, Goffinet

. Profound neutropenia during the early phase of haemodialysis. JAMA 1968; 203: 1135–7.

Craddock

, Fehr

, Dalmasso

, Brigham

, Jacob

. Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation of dialyser cellophane membranes. J Clin Invest 1977; 59: 979–88.

Foret

, Hachache

, Maftahi

, Milongo

, Kuentz

, Christollet

. The long-term evaluation of the biocompatibility of nine different haemodialysis membranes. Life Support Systems 1987; 5: 203–6.

Gurland

, Davison

, Bonomini

. Definitions and terminology in biocompatibility. Nephrol Dial Transplant 1994; 9(suppl 2): 4–10.

Garella

, Chang

. Hemodialysis-associated hypoxemia. Am J Nephrol 1984; 4: 273–9.

Duarte

. Blood pressure, ventilation and lipid imbalance during haemodialyis: effect of dialysate composition. Blood Purif 1985; 3: 199–214.

Igarashi

, Kioi

, Geijo

, Arakawa

. Physiologic approach to dialysis-induced hypoxemia; effects of dialyser materials and dialysate composition. Nephron 1985; 41: 62–9.

De Backer

, Verpooten

, Borgonjon

, Vermeire

, Lins

, DeBroe

. Hypoxemia during haemodialysis: effects of different membranes and dialysate composition. Kidney Int 1983; 23: 738–43.

DeBroe

. Hemodialysis-induced hypoxemia. Nephrol Dial Transplant 1994; 9(suppl 2): 173–5.

10.

Becker

, Schaefer

, Bömer

. In vivo viability of 111-ln-labelled granulocytes demonstrated in a sham dialysis. Br J Radiol 1989; 62: 462–7.

11.

Dodd

, Gordge

, Tarrant

, Parsons

, Weston

. A demonstration of neutrophil accumulation in the pulmonary vasculature during haemodialysis. Proc EDTA 1983; 20: 186–9.

12.

Flaherty

, Cheung

, Marshall

, Munger

. Cardio-pulmonary events during haemodialysis using various membranes and dialysate. J Am Soc Nephrol 1993; 4: 345.

13.

Sherlock

, Ledwith

, Letteri

. Hypoventilation and hypoxemia during haemodialysis: relfex response to removal of CO₂ across the dialyzer. Trans ASAIO 1977; 23: 406–10.

14.

Dumler

, Levin

. Leucopenia and hypoxemia, unrelated effects of hemodialysis. Arch Intern Med 1979; 139: 1103–6.

15.

Dolan

, Whipp

, Davidsons

, Weitzman

, Wasserman

. Hypnea associated with acetate haemodialysis: carbon dioxide-flow dependent ventilation. New Engl J Med 1981; 305: 72–5.

16.

Hakim

. Clinical implications of haemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484–94.

17.

Hakim

, Fearon

, Lazarus

. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984; 26: 194–200.

18.

Bousquet

, Michel

F.B.

. Allergy to formaldehyde and ethylene oxide. Clin Rev Allergy 1991; 9: 357–70.

19.

Hugli

. Structure and function of the anaphylatoxins. Springer Seminar Immunopathol 1984; 7: 193–219.

20.

Dolovich

, Bell

. Allergy to a product (s) of ethylene oxide gas: demonstration of IgE and IgG antibodies and hapten specificity. J Allergy Clin Immunol 1978; 62: 30–2.

21.

Lemke

H.D.

. Mediation of hypersensitivity reactions during hemodialysis by IgE antibodies against ethylene oxide. Artif Organs 1987; 11: 104–10.

22.

Bommer

, Ritz

. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis. Artif Organs 1987; 11: 111–7.

23.

Rumpf

K.W.

, Seubert

. Association of ethylene oxide-induced IgE antibodies with symptoms in dialysis patients. Lancet 1985; ii: 1385–87.

24.

Lemke

H.D.

, Heidland

, Schaefer

R.M.

. Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies. Nephrol Dial Transplant 1990; 5: 264–9.

25.

Schulman

E.S.

, Post

T.J.

, Henson

P.M.

, Giclas

P.C.

. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988; 81: 918–23.

26.

Siraganian

R.P.

, Hook

W.A.

. Complement-mediated release of histamine from human basophils. II. Mechanism of the histamine release reaction. J Immunol 1976; 116: 639–46.

27.

Hoerl

, Feinstein

, Wanner

, Frischmuth

, Goesele

, Massry

. Plasma levels of main granulocyte components during haemodialysis: comparison of new and reused dialysers. Am J Nephrol 1990; 10: 53–7.

28.

Sievers

, Stack

, Piering

, Cohen

. Determinants of dialyser reusability. ASAIO Trans 1991; 37: M185.

29.

Dumler

, Zasuwa

, Levin

. Effect of dialyser reprocessing method on complement activation and hemodialysers-related symptoms. Artif Organs 1987; 11: 128–31.

30.

Gagnon

, Kaye

. Hemodialysis neutropenia and dialyser reuse: role of the cleansing agent. Uremia Invest 1984; 8: 17–23.

31.

Gagnon

, Kaye

. Effect of cleansing agent on the biocompatibility of reused dialysers. In: Nose

, Kjellstrand

, Ivanovich

, eds. Progress in artificial organs. ISAO Press 1985; 965–9.

32.

Kuwahara

, Markert

, Wauters

. Biocompatibility aspects of dialyser reprocessing: a comparison of 3 reuse methods and 3 membranes. Clin Nephrol 1989; 32: 139–43.

33.

Daugirdas

, Potempa

, Dinh

, Gandhi

, Ivanovich

, Ing

. Plate, coil and hollow-fiber cuprammonium cellulose dialysers: discrepancy between incidence of anaphylactic reactions and degree of complement activation. Artif Organs 1987; 11: 140–3.

34.

Pegues

D.A.

, Beck-Sague

C.M.

, Woollen

S.W.

. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE-inhibitors. Kidney Int 1992; 42: 1232–7.

35.

Villaroel

. Incidence of hypersensitivity in haemodialysis. Artif Organs 1984; 8: 278–80.

36.

Kirschbaum

. The decline in serum albumin after conversion to high-flux, high-efficiency dialysis. Artif Organs 1994; 18: 729–35.

37.

Ikitzler

, Flakoll

, Parker

, Hakim

. Amino acid and albumin losses during haemodialysis. Kidney Int 1994; 46: 830–7.

38.

Kaplan

, Halley

, Lapkin

, Graeber

. Dialysate protein losses with bleach processed polysulphone dialysers. Kidney Int 1995; 47: 189–92.

39.

Port

. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46: 1728–37.

40.

Man

N.K.

, Cianconi

, Faivre

J.M.

. Dialysis-associated adverse reactions with high-flux membranes and microbial contamination of liquid bicarbonate concentrate. Contr Nephrol 1988; 62: 24–34.

41.

Nicholls

A.J.

, Platts

M.M.

. Anaphylactoid reactions due to haemodialysis, haemofiltration, or plasma separation. Br Med J 1982; 285: 1607–9.

42.

Tokars

, Alter

M.J.

, Favero

M.S.

, Moyer

L.A.

, Bland

L.A.

. National Surveillance of haemodialysis associated diseases in the United States, 1990. ASAIO J 1993; 39: 71–80.

43.

Yamagami

, Adachi

, Sugimura

. Detection of endotoxin antibody in long-term dialysis patients. Int J Artif Organs 1990; 13: 205–10.

44.

Bambauer

, Schaer

, Jung

, Daum

, Vienken

. Contamination of dialysis water and dialysate. ASAIO J 1994; 40: 678–82.

45.

Klein

, Pass

, Harding

, Wright

, Million

. Microbial and endotoxin contamination in water and dialysate in the Central United States. Artif Organs 1990; 14: 85–94.

46.

Quellhorst

, Schünemann

. Beta-2 amyloidosis and haemofiltration. In: Geijo

, Brancaccio

, Bardin

, eds. Dialysis amyloidosis. Wichtig Editore 1989; pp 123–9.

47.

Baz

, Durand

, Ragon

, Jaber

, Andrieu

, Merzouk

. Using ultrapure water in haemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681–5.

48.

Shaldon

, Deschodt

, Branger

. Haemodialysis hypotension: the interleukin hypothesis restated. Proc EDTA-ERA 1985; 22: 229–43.

49.

Fox

, Henderson

L.W.

. Cardiovascular response during haemodialsyis and hemofiltration: thermal, membrane and catecholamine influences. Blood Purif 1993; 11: 224–36.

50.

Bambauer

, Walther

, Meyer

. Bacteria and endotoxin-free dialysis fluid for use in chronic haemodialysis. Artif Organs 1994; 18: 188–92.

51.

Frinak

, Polaschegg

H.D.

, Levin

, Pohlod

, Dumler

, Saravolatz

. Filtration of dialysate using an on-line dialysate filter. Int J Artif Organs 1991; 14: 691–7.

52.

Abuelo

, Shemin

, Chazan

. Acute symptoms produced by haemodialysis: a review of their causes and associations. Seminars in Dialysis 1993; 6: 59–69.

53.

Rosa

A.A.

, Fryd

D.S.

, Kjellstrand

C.M.

. Dialysis symptoms and stabilization in long-term dialysis. Arch Intern Med 1980; 140: 804–7.

54.

Dumler

, Zasuwa

, Lewin

N.W.

. Effect of dialyzer reprocessing methods on complement activation and hemodialyzer-related symptoms. Artif Organs 1987; 11: 128–31.

55.

Bergamo collaborative dialysis study group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Kidney Int 1991; 40: 714–9.

56.

Collins

D.M.

, Lambert

M.B.

, Tannenbaum

J.S.

, Oliverio

, Schwab

S.J.

. Tolerance of haemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency haemodialysis. J Am Soc Nephrol 1993; 4: 148–54.

57.

Skroeder

N.R.

, Jacobson

S.H.

, Lins

L.E.

, Kjellstrand

C.M.

. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after haemodialysis. Trans ASAIO 1990; 36: M637–9.

58.

Teehan

, Schleifer

, Brown

, Sigler

, Raimondo

. Urea kinetic analysis and clinical outcome on CAPD. A five year longitudinal study. Adv Perit Dial 1991; 6: 181–5.

59.

Lowrie

, Lew

. Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–82.

60.

Gutierrez

, Alvestand

, Wahren

, Bergström

. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487–94.

61.

Gutierrez

, Alvestrand

, Bergström

. Membrane selection and muscle protein catabolism. Kidney Int 1992; 42(suppl 38): S86–90.

62.

Hoerl

W.H.

, Schaefer

, Heidland

. Effect of different dialyzers on proteinases and proteinase inhibitors during haemodialysis. Am J Nephrol 1985; 5: 320–6.

63.

Baracos

, Rodeman

, Dinarello

, Goldberg

. Stimulation of muscle protein degradation and prostaglandin E₂ release by leukocyte pyrogen (interleukin-1). New Engl J Med 1983; 308: 553–8.

64.

Dinarello

C.A.

, Wolff

S.M.

. Molecular basis of fever in humans. Am J Med 1982; 72: 799–819.

65.

Bingel

, Lonnemann

, Koch

K.M.

, Dinarello

, Shaldon

. Enhancement of in vitro human interleukin-1 production by sodium acetate. Lancet 1987; i: 14–6.

66.

Haeffner-Cavaillon

, Jahns

, Poignet

J.L.

, Kazatchkine

. Induction of interleukin-1 during haemodialysis. Kidney Int 1993; 43(suppl 39): 139–43.

67.

Lonnemann

, Bingel

, Floege

, Koch

K.M.

, Shaldon

, Dinarello

. Detection of endotoxin-like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 1988; 33: 29–35.

68.

Misfeldt

, Legaard

, Howell

, Fornella

, LeGrand

. Induction of interleukin-1 from murine peritoneal macrophages by Pseudomonas aeruginosa Exotoxin A. Infect Immun 1990; 58: 978–82.

69.

Goldberg

A.L.

, Kettelhut

I.C.

, Furuni

, Fagan

J.M.

, Baracos

. Activation of protein breakdown and prostaglandin E₂ production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin-1 or other known cytokines. J Clin Invest 1988; 81: 1378–83.

70.

Miller

, Hammerschmidt

, Anderson

, Moore

. Protein loss induced by complement activation during peritoneal dialysis. Kidney Int 1984; 25: 480–5.

71.

Arend

, Massoni

, Niemann

, Giclas

. Absence of induction of II-1 production in human monocytes by complement fragments. J Immunol 1989; 142: 173–8.

72.

Gutierrez

, Bergstöm

, Alvestrand

. Protein catabolism in sham–haemodialysis: the effect of different membranes. Clin Nephrol 1992; 38: 20–9.

73.

Gutierrez

, Bergström

, Alvestand

. Hemodialysis-associated protein catabolism with and without glucose in the dialysis fluid. Kidney Int 1994; 46: 814–22.

74.

Lim

, Bier

, Flanigan

, Sum-Ping

. The effect of haemodialysis on protein metabolism: a leucine kinetic study. J Clin Invest 1993; 91: 2429–36.

75.

Lewis

, Van Epps

, Chenoweth

. Leukocyte C5a receptor modulation during haemodialysis. Kidney Int 1987; 31: 112–20.

76.

Lindsay

, Bergstöm

. Membrane biocompatibility and nutrition in patients on maintenance haemodialysis. Nephrol Dial Transplant 1994; 9(suppl 2): 150–55.

77.

Van Ypersele de Strihou

, Floege

, Jadoul

, Koch

K.M.

. Amyloidosis and its relationship to different dialysers. Nephrol Dial Transplant 1994; 9(suppl. 2): 156–61.

78.

Miura

, Ischiyama

, Inomata

. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing longterm haemodialysis. Nephron 1992; 60: 268–73.

79.

Van Ypersele de Strihou

, Jadoul

, Malghem

, Maldague

, Jamart

. Effect of dialysis membrane and patients age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012–9.

80.

Hauglustaine

, Waer

, Michielson

. Haemodialysis membranes, serum β2-microglobulin, and dialysis amyloidosis. Lancet 1986; i: 1211–2.

81.

Bergström

, Wehle

. No change in corrected β2-m concentration after Cuprophan^® haemodialysis. Lancet 1987; i: 628–9.

82.

Floege

, Bartsch

, Schulze

, Shaldon

, Koch

K.M.

, Smeby

. Turnover of 131-β2-microglobulin in hemodialysed patients. J Lab Clin Med 1991; 118: 153–65.

83.

Vincent

, Chanard

, Caudwell

, Lavoud

, Wong

, Revillard

. Kinetics of ¹²⁵I-β2-microglobulin turnover in dialysed patients. Kidney Int 1992; 42: 1434–43.

84.

Odell

, Slowiaczek

, Moran

, Schindhelm

. β2-microglobulin kinetics in end-stage renal failure. Kidney Int 1991; 39: 909–19.

85.

van Ypersele de Strihou

, Floege

, Jadoul

, Koch

. Amyloidosis and its relationship to different dialysers. Nephrol Dial Transplant 1994; 9(supplement 2): 156–61.

86.

Zaoui

, Stone

, Hakim

. Effects of dialysis membranes on β2-microglobulin production and cellular expression. Kidney Int 1990; 38: 962–8.

87.

Schoels

, Jahn

, Hug

, Deppisch

, Ritz

, Hänsch

. Stimulation of mononuclear cells by contact with Cuprophan^® membranes: further increase of β2-microglobulin synthesis by activated late complement components. Am J Kidney Dis 1993; 21: 394–99.

88.

Knudsen

, Leon

, Ng

, Shaldon

, Floege

, Koch

. Hemodialysis-related induction of β2-m and interleukin-1 and release by mononuclear phagocytes. Nephron 1989; 188–93.

89.

Campistol

, Molina

, Bernard

. Synthesis of β2-m in lymphocyte culture: role of haemodialysis, dialysis membranes, dialysis amyloidosis and lymphokines. Am J Kidney Dis 1993; 22: 691–9.

90.

Paczek

, Schäfer

, Heidland

. Dialysis membranes inhibit in vitro release of β2-m from human lymphocytes. Nephron 1990; 56: 267–70.

91.

Campistol

, Molina

, Rodriguez

, Mirapeix

, Munoz-Gomez

, Revert

. Dialysis membranes inhibit synthesis and release of β2-m in lymphocyte cultures. Nephron 1991; 59: 691–2.

92.

Miyata

, Inagi

, lida

. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521–6.

93.

Levin

, Dumler

, Zasuwa

, Stalla

. Mortality comparison between conventional and high flux dialysis. J Am Soc Nephrol 1990; 1: 365.

94.

Levin

, Zasuwa

, Dumler

. Effect of membrane type on causes of death in haemodialysis patients. J Am Soc Nephrol 1991; 2: 335.

95.

Hornberger

, Chernew

, Petersen

, Garber

. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227–37.

96.

Hakim

, Wingard

, Parker

. Effect of the dialysis membrane in the treatment of patients with acute renal failure. New Engl J Med 1994; 331: 1338–42.

97.

Simpson

, Allison

. Dialysis and acute renal failure: can mortality be improved? Nephrol Dial Transplant 1993; 8: 946 (Abstract).

98.

Owen

W.F.

, Lew

N.L.

, Liu

, Lowrie

E.G.

, Lazarus

J.M.

. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing haemodialysis. New Engl J Med 1993; 329: 1001–6.

99.

Bergoström

, Alvestrand

, Fürst

. Plasma and muscle free amino acids in maintainance hemodialysis patients without protein in malnutrition. Kidney Int 1990; 38: 108–14.

100.

Eknoyan

, Nissenson

, Beck

, Schulman

. The mortality and morbidity in haemodialysis study: ethical issues. Seminars in Dialysis 1994; 7: 369–72.

101.

Parker

T.F.

, Hakim

R.M.

. Interelationships of dialysis prescription, protein catabolic rate and morbidity/mortality with dialyzer biocompatibility. Blood Purif 1993; 11: 341–2.

102.

Kaplan

. What are the important considerations in the care of critically ill patients with acute renal failure? Seminars in dialysis 1994; 7: 103–6.

103.

Charra

, Calemard

, Ruffet

. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286–91.

104.

Parker

T.F.

, Husni

, Huang

, Lew

, Lowrie

E.G.

. Dallas Nephrology Associates. Survival of haemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23: 670–80.

105.

Bonomini

, Coli

, Feliciangeli

, Nanni-Costa

, Scolari

. Long-term comparative evaluation of synthetic and cellulosic membranes in dialysis. Int J Artif Organs 1994; 17: 392–8.